Table 5.
Replication: hazard ratios (95 % CI) of the differentially methylated positions associated with arsenic-mediated CVD incidence in the Strong Heart Study in three diverse US populations (Framingham Heart Study, Women’s Health Initiative, and Multi-Ethnic Study of Atherosclerosis).
| CpG | Gene | Strong Heart Study | Framingham Heart Study | Women’s Health Initiative | Multi-Ethnic Study of Atherosclerosis |
|---|---|---|---|---|---|
| cg01178924 | LMO7 | 0.86 (0.73, 1.02) | 0.83 (0.60, 1.14) | 1.15 (0.94, 1.40) | 1.03 (0.57, 1.85) |
| cg01270753 | TGFBR1 | 0.60 (0.50, 0.73) | - | - | 1.03 (0.52, 2.03) |
| cg01542019 | TECR | 1.14 (0.96, 1.36) | 1.06 (0.74, 1.52) | 1.26 (1.03, 1.54) | 1.59 (0.78, 3.25) |
| cg02047803 | RELL2 | 0.77 (0.65, 0.92) | 0.76 (0.54, 1.07) | 1.02 (0.82, 1.26) | 1.77 (0.91, 3.42) |
| cg03362418 | TYMP | 0.60 (0.48, 0.74) | - | - | 3.36 (1.44, 7.83) |
| cg03497652 | ANKS3 | 1.50 (1.24, 1.82) | 2.32 (1.58, 3.40) | 1.15 (0.91, 1.44) | 2.36 (1.10, 5.06) |
| cg05779585 | LOC286083 | 0.89 (0.84, 0.95) | 0.87 (0.69, 1.09) | 1.18 (0.99, 1.40) | 4.02 (1.89, 8.57) |
| cg06668829 | EPPK1 | 1.44 (1.21, 1.72) | 0.77 (0.53, 1.11) | 1.15 (0.92, 1.44) | 1.96 (0.92, 4.20) |
| cg06716655 | ADAR2 | 0.76 (0.64, 0.9) | - | - | 0.57 (0.27, 1.17) |
| cg06970472 | APBB2 | 0.72 (0.59, 0.88) | 0.64 (0.41, 0.99) | 0.93 (0.73, 1.18) | 3.97 (1.93, 8.19) |
| cg09956442 | ARRDC2 | 0.71 (0.59, 0.85) | - | - | 0.89 (0.45, 1.76) |
| cg11946459 | HLA-A | 0.76 (0.63, 0.92) | 0.65 (0.46, 0.92) | 0.86 (0.70, 1.06) | 1.41 (0.71, 2.83) |
| cg13092901 | TYMP | 0.59 (0.48, 0.72) | 0.54 (0.34, 0.87) | 0.80 (0.63, 1.00) | 1.19 (0.53, 2.67) |
| cg14827056 | EIF2C2 | 1.41 (1.17, 1.69) | 1.47 (1.01, 2.13) | 1.21 (0.95, 1.54) | 1.41 (0.68, 2.89) |
| cg16335098 | SMOC2 | 0.89 (0.80, 0.99) | - | 1.08 (0.94, 1.25) | 0.89 (0.62, 1.28) |
| cg17608381 | HLA-A | 0.77 (0.64, 0.92) | 0.62 (0.45, 0.87) | 0.88 (0.72, 1.07) | 0.93 (0.50, 1.73) |
| cg18032342 | NISCH | 1.27 (1.07, 1.50) | - | - | 1.99 (1.06, 3.75) |
| cg18618815 | COL1A1 | 0.63 (0.52, 0.76) | 0.52 (0.35, 0.78) | 1.05 (0.85, 1.30) | 0.85 (0.41, 1.79) |
| cg19693031 | TXNIP | 0.51 (0.43, 0.59) | 0.72 (0.50, 1.02) | 0.76 (0.62, 0.92) | 0.93 (0.50, 1.70) |
| cg22294740 | LINGO3 | 1.42 (1.19, 1.69) | 1.84 (1.31, 2.59) | 1.21 (0.97, 1.50) | 3.87 (2.03, 7.38) |
| cg23027596 | UBAC1 | 0.65 (0.54, 0.79) | - | - | 0.90 (0.42, 1.95) |
Models adjusted for age, sex, smoking status, BMI and cell counts (CD8T, CD4T, NK, B cells [eosinophils for MESA] and monocytes) for all populations. Additionally adjusted for total cholesterol in the FHS, for LDL cholesterol, study center (Arizona, Oklahoma or North and South Dakota) and genetic PCs in the SHS, for LDL cholesterol, technical covariates (plate number and pull ID) and race in the WHI, and for race, site and LDL cholesterol in MESA.